Technology
Upcoming Earnings
Health
AVROBIO
$18.609876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$18.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.97 (5.50%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell AVROBIO and other stocks, options, ETFs, and crypto commission-free!
About
AVROBIO, Inc. Common Stock, also called AVROBIO, is a clinical stage company that engages in the development of disruptive therapies. Read More It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. The company was founded by Jeffrey Medin and Christopher Paige in 2015 and is headquartered in Cambridge, MA.
CEO
Employees
24
Headquarters
Cambridge, Massachusetts
Founded
2015
Market Cap
418.87M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
171.24K
High Today
$18.69
Low Today
$17.63
Open Price
$17.71
Volume
90.12K
52 Week High
$53.70
52 Week Low
$11.85
Collections
Technology
Upcoming Earnings
Health
Biotechnology
Medical
Therapy
2018 IPO
US
News
MarketBeatMar 3
Stock Price, News, & Analysis for Avrobio
AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical tria...
Price Paid on Robinhood
2% Lower
Right Now
52 Week Low
$11.85
Average Price Paid
$19.00
52 Week High
$53.70
Earnings
-$2.98
-$2.15
-$1.32
-$0.49
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.57 per share
Actual
Expected Mar 21, Pre-Market